STOCS-H Scottish TOC Study HPV test comparison

Similar documents
The Predictors Studies (1, 2 & 3) A comparison of tests for high grade CIN in women with abnormal smears and in a screening population

The clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way

Pushing the Boundaries of the Lab Diagnosis in Asia

Human Papillomaviruses: Biology and Laboratory Testing

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Focus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection

OBJECTIVES. Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections

Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Performance of the Aptima High-Risk Human Papillomavirus mrna Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology

P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.

Molecular Triage: Partial and Extended Genotyping and More!

Epigenetic markers on the horizon: how to triage hrhpv positive women

Modernization of your cytology laboratory and Co-Testing Approach for Cervical Screening

Advanced Molecular Diagnostic Systems

Role and Outputs of the Scottish HPV Reference Laboratory

News. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays

The Biology of HPV Infection and Cervical Cancer

Safe, Confident, QIAsure

Cervical cancer prevention: Advances in primary screening and triage system

INTEGRATING HPV TESTING IN CERVICAL CANCER SCREENING PROGRAMS

Disclosures Teresa M Darragh, MD

Natural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma

VALGENT (validation of HPV genotyping assays) implications for the introduction of primary HPV screening

Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force

Type-Specific Human Papillomavirus E6/E7 mrna Detection by Real-Time PCR Improves Identification of Cervical Neoplasia

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Cervical Cancer Screening. David Quinlan December 2013

HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests

Evidence-based treatment of a positive HPV DNA test. Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR

SOME ETIOLOGIES OF STI OBJECTIVES CHLAMYDIA TRENDING. Things are Heating Up: An Update on Emerging Sexually-transmitted Infection Agents

Figures relating to potential impact

Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018

Clinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m

POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH

Diagnostics HPV Testing

Detect Cervical Cancer ReachMD Page 1 of 7

Jean-Christophe Noël and Philippe Simon. 1. Introduction

UPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH. Dr Arlo Upton Clinical Microbiologist Labtests Auckland

HPV AND CERVICAL CANCER

Commercial Assays an Overview. Molecular Workshop

Update on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories

HPV Primary Screening Update. Prof. Vu Ba Quyet Director of NO&G hospital

K Cuschieri, Scottish HPV Reference Lab Presented at SMVN Laboratories and Specialised Services Meeting, March 2013

He Said, She Said: HPV and the FDA. Audrey P Garrett, MD, MPH June 6, 2014

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Use of HPV testing for cervical screening in vaccinated women - insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.

Future Directions for HPV and Cervical Screening. Jane Grant Metro Auckland Cervical Screening Forum June 2017

Menu and flexibility with the QIAscreen HPV PCR Test

Hosp Lab Management (HLM) Service. HLM Tie-ups Cervical Screening & Diagnostics Tie-up Business Process Flow

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

HEV Assay Development Update

No HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)

(Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to

MEDICAL POLICY. SUBJECT: CERVICAL CANCER SCREENING and HUMAN PAPILLOMA VIRUS (HPV) TESTING

The data from the ATHENA study and others bring this expectation and the appropriateness of the guidelines for women aged into question.

The Introduction of Primary HPV Screening in Australia

I have no financial interests in any product I will discuss today.

CINtec PLUS and the Pap smear: a co-testing alternative

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme Sherlaw-Johnson C, Philips Z

Why HPV Screening Which Problems What Methods

Title: An evaluation of a novel single tube method for extended genotyping of Human

New CT/GC Tests. CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009

32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com

Preventing cervical cancer Australia. The Renewed National Cervical Screening Program 2019 Common Questions and Cases

The new Cervical Screening Test for Australian women: Louise Farrell

CADTH OPTIMAL USE REPORT HPV Testing for Primary Cervical Cancer Screening Project Protocol

I have no financial interests in any product I will discuss today.

Industry Sponsored Symposia. Québec City, CANADA JULY 10 TO 13,

Trends in molecular diagnostics

Schedule of Accreditation

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

The effects of immunisation on infection and Disease

1/12/2016. I do not engage in any lucrative deals that require disclosure.

Adjunctive colposcopy technologies for examination of the uterine cervix DySIS, LuViva Advanced Cervical Scan and Niris Imaging System

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

POET REPORT Perspectives on Emerging Technology

Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

The impact of the HPV vaccine in Scotland.

Over-diagnoses in Cytopathology: Is histology the gold standard?

National Surveillance System for Human Papillomavirus Infection and Related Disease in Scotland

Jefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014

FOR EXPORT ONLY. Not for sale in the United States of America.

for Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James SoGAT 2009

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

Woo Dae Kang, Ho Sun Choi, Seok Mo Kim

The Compass trial: Informing changes to the National Cervical Screening Program

November 2012 Volume: TMRCHPV CYTOLOGY AND HPV TESTING WORLD MARKETS (SAMPLE COPY, NOT FOR RESALE)

Aptima HPV E6/E7 mrna Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer

Beyond Pap Morphological Triage: p16/ki67 Dual Staining

Biomed Environ Sci, 2015; 28(1): 80-84

University of Groningen. New insights in methodology of screening for cervical cancer Wang, Rong

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

HPV Testing What are EQAS and QC data telling us?

QIAsure Methylation Test a breakthrough solution in Women s Health

Transcription:

STOCS-H Scottish TOC Study HPV test comparison

What is entailed? Trial of new HPV tests on residual sample after HC2 result obtained, reported and acted on Complements English Sentinel Sites HPV Multi-test Study, on Triage samples and due to report in September Aim is to provide sufficient comparative data to be able to make recommendations as to which HPV tests are acceptable within CSP Similar process undertaken for new tests in other areas of diagnostic medicine all labs undertaking diagnostic testing free to use whichever CE marked and recommended test best suits their set-up and existing repertoire Similar BBV and Chlamydia/GC test comparisons recently

Qiagen Hybrid Capture for HR-HPV DNA detection 2. Rapid Capture System - 1. Manual HC2 Automated solution for high throughput HPV testing FDA approval 2004 Used in Sentinel sites Being made available by Qiagen for TOC Early Implementers at no additional cost provided SHPVRL can find bench space for platform

Which HPV tests for STOCS-H? Abbott rthpv uses real-time PCR; detects HPV DNA with limited typing data (HPV 16; HPV 18; HPV other HR ) GenProbe APTIMA HPV broad spectrum HPV mrna detection using transcription-mediated amplification system Hologic Cervista HPV uses Invader chemistry ; detects HPV DNA in 3 wells, typing at species level Roche cobas 4800 HPV - uses realtime PCR; detects HPV DNA with limited typing data (HPV 16; HPV 19; HPV other HR ) Abbott rthpv trialled by SHPVRL for MAVARIC trialin comparison with HC2; Results also used for Phase 1 of Sentinel Multi-test study. Same platform used in Edinburgh for Chlamydia and GC NAATs GenProbe APTIMA HPV tested by SHPVRL in EAS performance comparison with HC2 for detection of CIN2+ in women attending Colposcopy; Platform used for GC confirmation in Edinburgh Hologic Cervista HPV manual version 1 tested by HPV Research Group, reproducibility increased significantly with automated DNA extraction; results also used for Phase 1 of Sentinel Multi-test study Roche cobas 4800 HPV - not yet trialled by SHPVRL, but experience in Lab with same platform for BBV

Abbott rt HPV Roche cobas 4800 HPV Qualitative real time PCR technology Detects 14 high risk HPV genotypes Detects HPV16 &18 separately Detects 12 other HR-HPV: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 Qualitative real time PCR technology Detects 14 high risk HPV genotypes Detects HPV16 &18 separately Detects same 12 other HR-HPV Fully automated sample preparation

GenProbe APTIMA HPV CE marked and launched in Europe in 2008 Detects 14 high-risk HPV types through mrnas to E6 and E7 that are made in higher amounts when HPV infections progress toward cervical cancer. Designed to run on fully automated, high throughput TIGRIS instrument system and and on the smaller PANTHER instrument not yet available in UK EAS uses GenProbe s semi-automated DTS instrument platform

Hologic Cervista HPV HR March 2009: Cervista HPV HR approved by FDA as an in vitro diagnostic for use: To screen patients with atypical squamous cells of undetermined significance (ASC-US) cervical cytology to determine the need for referral to colposcopy To screen adjunctively with cervical cytology to assess the presence or absence of high-risk HPV types in women 30 years and older Uses Invader chemistry: a biplex isothermal reaction process

HPV Predictors 2 Study Courtesy of Anne Szarewski, November 2011, SACC, Edinburgh

Abbott HPV DNA using real-time PCR HPV DNA 16,18 and 12 others Automated test platform Comparable to HC2 in Predictors No sample processing front end Conclusions GenProbe HPV mrna using TMA Semi-Automated and automated test platforms Comparable to HC2 in Predictors Broad spectrum detection, no typing No sample processing front end Hologic HPV DNA using Invader chemistry Full sample processing front end Fits with Scottish LBC systems Automated test platform HPV DNA Species 9, 7 and 5/6 (16,31,33,35,52,58); (18,39,45,59,68); (51,56,66) No UK Comparisons with HC2 yet Roche HPV DNA using real-time PCR Full sample processing front end HPV DNA 16,18 and 12 others Automated test platform Well established platform but no local HPV experience as yet